Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Research analysts at Gabelli raised their FY2017 EPS estimates for Lexicon Pharmaceuticals in a note issued to investors on Thursday. Gabelli analyst K. Kedra now forecasts that the biopharmaceutical company will post earnings of ($1.55) per share for the year, up from their prior forecast of ($1.65).
Several other analysts have also issued reports on LXRX. Zacks Investment Research lowered Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 17th. Needham & Company LLC reissued a “buy” rating on shares of Lexicon Pharmaceuticals in a report on Friday, January 27th. Wedbush reissued an “outperform” rating and set a $33.00 target price on shares of Lexicon Pharmaceuticals in a report on Wednesday, February 8th. HC Wainwright reissued a “buy” rating and set a $27.00 target price (up from $26.00) on shares of Lexicon Pharmaceuticals in a report on Wednesday, March 1st. Finally, Citigroup Inc increased their target price on Lexicon Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, March 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $26.67.
Lexicon Pharmaceuticals (NASDAQ:LXRX) traded down 0.50% during midday trading on Monday, reaching $15.80. 57,391 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $14.83 and a 200 day moving average price of $15.14. Lexicon Pharmaceuticals has a 12 month low of $11.52 and a 12 month high of $19.62. The company’s market cap is $1.66 billion.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Friday, March 3rd. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.51) by $0.20. Lexicon Pharmaceuticals had a negative net margin of 11.87% and a negative return on equity of 9.46%. The firm had revenue of $23 million for the quarter, compared to the consensus estimate of $15.56 million. During the same quarter in the previous year, the company earned $0.76 earnings per share. The business’s revenue was down 81.9% compared to the same quarter last year.
A number of hedge funds have recently added to or reduced their stakes in LXRX. State Street Corp raised its stake in Lexicon Pharmaceuticals by 17.2% in the fourth quarter. State Street Corp now owns 1,591,365 shares of the biopharmaceutical company’s stock valued at $22,008,000 after buying an additional 233,371 shares during the period. Russell Investments Group Ltd. purchased a new position in Lexicon Pharmaceuticals during the fourth quarter valued at approximately $1,242,000. Candriam Luxembourg S.C.A. increased its position in Lexicon Pharmaceuticals by 52.3% in the third quarter. Candriam Luxembourg S.C.A. now owns 195,000 shares of the biopharmaceutical company’s stock valued at $3,524,000 after buying an additional 67,000 shares in the last quarter. D. E. Shaw & Co. Inc. increased its position in Lexicon Pharmaceuticals by 238.1% in the third quarter. D. E. Shaw & Co. Inc. now owns 667,130 shares of the biopharmaceutical company’s stock valued at $12,055,000 after buying an additional 469,827 shares in the last quarter. Finally, HBK Investments L P purchased a new position in Lexicon Pharmaceuticals during the third quarter valued at approximately $1,263,000.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.